Dr. Borgen Discusses the Patents on BRCA1 and BRCA2

Patrick Borgen, MD
Published Online: Monday, April 8, 2013
Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the patents on BRCA1 and BRCA2.

Of the 20,000 human genes, about 4,000 are protected under patent or intellectual property rights, Borgen says, making BRCA1 and BRCA2 not all that unique. The American Civil Liberties Union has filed lawsuits arguing that these patents infringe upon the rights of researcher, geneticists, and patients.

As a practicing physician, Borgen has done research with BRCA1 and BRCA2 and has never been impeded by Myriad Genetics. In some ways, Borgen feels that physicians are lucky to have a singe reference laboratory to trust.

Online CME Activities
Free CME from PER
Community Practice Connections: 13th Annual International Congress on the Future of Breast Cancer®
Highlights From the 13th Annual International Congress on the Future of Breast Cancer®
Pancreatic Cancer: Novel and Emerging Approaches to Early Detection and Treatment
Oncology Best Practice: Challenges in Treating Chronic Lymphocytic Leukemia – The Older Patient and Comorbid Conditions
More Reading
$auto_registration$